Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Vomiting 1Nausea 1Lung Neoplasms 1Esophageal Neoplasms 1

Interventions

Fluorouracil 13pembrolizumab 12Paclitaxel 12Oxaliplatin 12Leucovorin 9Carboplatin 9Capecitabine 8Trastuzumab 7Nivolumab 7Cisplatin 7Radiotherapy 6Radiation 6Taxes 5Esophagectomy 5Drug Therapy 5Surgical Procedures, Operative 4Specimen Handling 4Irinotecan 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Radiotherapy, Intensity-Modulated 3Proton Therapy 3Immunotherapy 3zanidatamab 2ulixertinib 2trastuzumab biosimilar HLX02 2relatlimab 2durvalumab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Palonosetron × 90 days × Clear all
NCT07617246 2026-06-01

The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
120 enrolled
GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡